Targeting cap-dependent translation via EIF4G1 scaffold can disrupt the expression of multiple oncogenic pathways that are associated with tumor progression, offer an excellent target in therapy-resistant cancers (Fig. 8). This evidence concerns the gene EIF4G1 and cancer.